89biologo.png
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 06, 2023 16:36 ET | 89bio, Inc.
SAN FRANCISCO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
89biologo.png
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
December 04, 2023 07:00 ET | 89bio, Inc.
—Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology— —Outcomes trial in F4 cirrhotic NASH...
89biologo.png
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
November 27, 2023 08:00 ET | 89bio, Inc.
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and...
89biologo.png
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
November 21, 2023 16:01 ET | 89bio, Inc.
SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
November 12, 2023 12:15 ET | 89bio, Inc.
—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24— —A...
89biologo.png
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 08, 2023 16:01 ET | 89bio, Inc.
–Pegozafermin granted Breakthrough Therapy Designation (BTD) for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis– –Feedback from regulatory agencies on pegozafermin Phase 3...
89biologo.png
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
October 17, 2023 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023 16:05 ET | 89bio, Inc.
SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89biologo.png
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
September 21, 2023 08:00 ET | 89bio, Inc.
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the...
89biologo.png
89bio to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023 08:00 ET | 89bio, Inc.
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...